Clinical Trial Details

Overview

Research Study Summary

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration- CEDAR STUDY

Purpose

This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.

To Learn more

CW ID: 212055
Date Last Changed: December 2, 2015

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
50 and up
Overall Status
Recruiting
Lead Sponsor
Allergan
Duration
96 Weeks
Facility Type
Out-Patient

Eligibility

Inclusion Criteria:

  • Diagnosis of age-related macular degeneration in at least 1 eye
  • Best corrected visual acuity of 20/40 to 20/320 in the study eye
  • Best corrected visual acuity of 20/200 or better in the non-study eye

Exclusion Criteria:

  • History of vitrectomy, macular surgery, or glaucoma surgery in the study eye
  • Cataract or refractive surgery in the study eye within the last 3 months

More Info

Protocol Number: 150998-005

Contact

Susan Sherouse
University of South Florida- USF Eye Institute
13127 Magnolia Drive
Tampa, FL 33612
Phone: 813-974-0948

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.